on CROSSJECT (EPA:ALCJ)
CROSSJECT Reports First Half of 2025 Financial Results and Updates
CROSSJECT, a pharmaceutical firm focusing on emergency treatments, has updated its financial performance for the first half of 2025. The company's cash reserves stood at €6.3 million by June 2025, a slight decline from €7.0 million at the end of 2024. Despite this, research and development expenses remained stable, supported by €6.5 million in reimbursements from BARDA related to ZEPIZURE® development.
The firm is progressing on submitting an Emergency Use Authorization for ZEPIZURE® with BARDA, having produced necessary validation batches. Post-June, an additional €11.3 million in R&D funding was secured, alongside a €750,000 credit line. CROSSJECT also achieved ISO 13485 certification renewal and saw the expansion of its Good Manufacturing Practices (GMP) certificate.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news